(Q51471682)

5 April 2018

title

Metabolic effects of telmisartan and irbesartan in type 2 diabetic patients with metabolic syndrome treated with rosiglitazone. (English)

1 reference

5 April 2018

1 reference

1

1 reference

5 April 2018

Angela D'Angelo

3

1 reference

5 April 2018

Arrigo F. Cicero

4

1 reference

5 April 2018

author name string

E Fogari

2

1 reference

5 April 2018

S A T Salvadeo

5

1 reference

5 April 2018

P D Ragonesi

6

1 reference

5 April 2018

I Ferrari

7

1 reference

5 April 2018

A Gravina

8

1 reference

5 April 2018

R Fassi

9

1 reference

5 April 2018

R Fogari

10

1 reference

5 April 2018

publication date

1 June 2007

1 reference

5 April 2018

Journal of Clinical Pharmacy and Therapeutics

published in

1 reference

5 April 2018

volume

32

1 reference

5 April 2018

issue

3

1 reference

5 April 2018

page(s)

261-268

1 reference

5 April 2018

Treating high blood pressure in diabetes: the evidence

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2007.00820.X

Angiotensin receptor blockers: therapeutic targets and cardiovascular protection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2007.00820.X

AT(1)-receptor blockers: differences that matter

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2007.00820.X

Molecular characterization of new selective peroxisome proliferator-activated receptor gamma modulators with angiotensin receptor blocking activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2007.00820.X

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2007.00820.X

Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2007.00820.X

The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2007.00820.X

Body fat mass and macronutrient intake in relation to circulating soluble leptin receptor, free leptin index, adiponectin, and resistin concentrations in healthy humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2007.00820.X

Can the atherosclerosis prevention targets be achieved in type 2 diabetes?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2007.00820.X

Preventing renal complications in diabetic patients: the Diabetics Exposed to Telmisartan And enalaprIL (DETAIL) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2007.00820.X

Replacement of valsartan and candesartan by telmisartan in hypertensive patients with type 2 diabetes: metabolic and antiatherogenic consequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2007.00820.X

The effect of irbesartan in reducing cardiovascular risk in hypertensive type 2 diabetic patients: an observational study in 16,600 patients in primary care

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2007.00820.X

Prevention and treatment of diabetic nephropathy: the program for irbesartan mortality and morbidity evaluation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2007.00820.X

Effects of doxazosin and irbesartan on blood pressure and metabolic control in patients with type 2 diabetes and hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2007.00820.X

Effects of telmisartan compared with eprosartan on blood pressure control, glucose metabolism and lipid profile in hypertensive, type 2 diabetic patients: a randomized, double-blind, placebo-controlled 12-month study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2007.00820.X

Comparison of the effects of telmisartan and nifedipine gastrointestinal therapeutic system on blood pressure control, glucose metabolism, and the lipid profile in patients with type 2 diabetes mellitus and mild hypertension: a 12-month, randomized,

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2007.00820.X

Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2007.00820.X

Long-term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12-month, double-blind, randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2007.00820.X

PPARgamma-activating angiotensin type-1 receptor blockers induce adiponectin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2007.00820.X

Peroxisome proliferator-activated receptor gamma (PPAR-gamma) agonist increases plasma adiponectin levels in type 2 diabetic patients with proteinuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2007.00820.X

Distinct properties and advantages of a novel peroxisome proliferator-activated protein [gamma] selective modulator

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2007.00820.X

Modulation of PPARgamma activity with pharmaceutical agents: treatment of insulin resistance and atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2007.00820.X

Corepressors selectively control the transcriptional activity of PPARgamma in adipocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2007.00820.X

10.1111/J.1365-2710.2007.00820.X

21 January 2018

Identifiers

DOI

1 reference

5 April 2018

1 reference

5 April 2018